|
Patent landscape, scope, and claims: |
United States Patent 11,053,214: Analysis of Scope, Claims, and Landscape
United States Patent 11,053,214, titled "STABILIZED AMORPHOUS DISPERSIONS OF APREPITANT AND METHODS OF PREPARATION THEREOF," describes solid amorphous dispersions of aprepitant, a neurokinin-1 (NK1) receptor antagonist. The patent focuses on improving the solubility and bioavailability of aprepitant, a compound with known challenges in these areas due to its poor aqueous solubility. The claimed technology aims to provide enhanced therapeutic efficacy for conditions treatable with NK1 receptor antagonists, such as chemotherapy-induced nausea and vomiting (CINV).
What are the core claims of Patent 11,053,214?
The patent's independent claims define specific compositions and methods for their preparation. Key claims focus on the following:
- Claim 1: A stabilized amorphous dispersion comprising aprepitant and at least one polymeric excipient, wherein the amorphous dispersion is essentially free of crystalline aprepitant. This claim is central to the patent, establishing the amorphous nature of the aprepitant as a primary feature. The patent specifies that "essentially free of crystalline aprepitant" means the crystalline content of aprepitant is less than 5% by weight of the total aprepitant present.
- Claim 6: A pharmaceutical composition comprising the stabilized amorphous dispersion of aprepitant as claimed in claim 1, and at least one pharmaceutically acceptable carrier. This broadens the protection to include the final dosage form.
- Claim 11: A method for preparing a stabilized amorphous dispersion of aprepitant, comprising: (a) providing a solution of aprepitant and at least one polymeric excipient in a suitable solvent; and (b) removing the solvent to obtain the stabilized amorphous dispersion. This claim covers the manufacturing process, specifically highlighting solvent-based techniques like spray drying or hot melt extrusion as preferred methods.
The patent also includes dependent claims that further define the polymeric excipients, solvent systems, and specific physical characteristics of the amorphous dispersion, such as glass transition temperature and particle size distribution.
What are the specific polymeric excipients and solvent systems disclosed?
The patent provides a non-exhaustive list of suitable polymeric excipients and solvent systems designed to create and stabilize the amorphous form of aprepitant.
Polymeric Excipients
The patent claims the use of at least one polymeric excipient to stabilize the amorphous dispersion. Examples provided include:
- Polyvinylpyrrolidone (PVP), including povidone K15, K30, and K90.
- Copovidone.
- Hydroxypropyl cellulose (HPC).
- Hydroxypropyl methylcellulose (HPMC).
- Hydroxypropyl methylcellulose acetate succinate (HPMC-AS).
- Methacrylic acid copolymers (e.g., Eudragit L100, S100).
- Polyvinyl acetate.
- Polyethylene glycol (PEG) with molecular weights ranging from 3000 to 20000.
- Polyvinyl alcohol (PVA).
The selection of the polymeric excipient is crucial for maintaining the amorphous state and preventing recrystallization of aprepitant. The patent suggests specific ratios of aprepitant to polymeric excipient, often ranging from 1:1 to 1:9 by weight, to achieve optimal stabilization.
Solvent Systems
The preparation methods described in the patent utilize various organic solvents or mixtures thereof. These solvents are selected for their ability to dissolve both aprepitant and the chosen polymeric excipient. Common examples cited include:
- Alcohols (e.g., methanol, ethanol, isopropanol).
- Ketones (e.g., acetone, methyl ethyl ketone).
- Esters (e.g., ethyl acetate, isopropyl acetate).
- Halogenated hydrocarbons (e.g., dichloromethane).
- Ethers (e.g., tetrahydrofuran).
- Acids (e.g., acetic acid).
The patent emphasizes that the solvent is removed, typically through evaporation or drying, leaving behind the amorphous solid dispersion.
How does this patent impact the market for Aprepitant formulations?
Patent 11,053,214 provides a mechanism to overcome the inherent poor solubility of aprepitant, which can limit its oral bioavailability and therapeutic effectiveness. By creating a stabilized amorphous form, the patent aims to enable the development of more potent and efficient aprepitant-based drugs. This has direct implications for the market in several ways:
- Extended Market Exclusivity: For the patent holder, this patent can provide a period of market exclusivity for improved aprepitant formulations, potentially delaying generic competition for specific delivery systems.
- New Product Development: Pharmaceutical companies can leverage the technology claimed in this patent to develop novel aprepitant formulations with enhanced pharmacokinetic profiles. This could lead to new indications or improved patient compliance.
- Generic Competition Considerations: Generic manufacturers seeking to produce aprepitant formulations will need to carefully navigate the claims of this patent. Formulations that utilize stabilized amorphous dispersions as described may infringe upon the patent.
- Therapeutic Advancements: The improved solubility and bioavailability offered by amorphous dispersions can lead to more effective treatments for conditions like CINV, potentially improving patient outcomes.
The patent claims are broad enough to encompass various amorphous dispersion technologies, including spray drying and hot melt extrusion, which are common manufacturing methods.
What is the patent landscape surrounding Aprepitant and NK1 Receptor Antagonists?
The patent landscape for aprepitant and NK1 receptor antagonists is characterized by numerous patents covering the compound itself, its synthesis, various salt forms, polymorphs, and different formulation strategies. United States Patent 11,053,214 is one such formulation patent aimed at improving drug delivery.
Key Areas of Patenting for Aprepitant:
- Composition of Matter Patents: Original patents covering the aprepitant molecule itself, which have largely expired or are nearing expiration, paving the way for generic versions.
- Process Patents: Patents related to novel or improved methods of synthesizing aprepitant, which can extend exclusivity for specific manufacturing routes.
- Polymorph Patents: Patents covering specific crystalline forms (polymorphs) of aprepitant that may have different physical properties, such as stability or dissolution rates.
- Formulation Patents: A significant area of patenting, including patents like 11,053,214, that focus on enhancing solubility, bioavailability, and stability. This includes amorphous solid dispersions, lipid-based formulations, and controlled-release systems.
- Method of Use Patents: Patents claiming the use of aprepitant for specific therapeutic indications, such as CINV, post-operative nausea and vomiting (PONV), and potentially other conditions mediated by the NK1 receptor.
Landscape for NK1 Receptor Antagonists:
The broader landscape for NK1 receptor antagonists includes other compounds with similar mechanisms of action. Patents in this area cover:
- New Chemical Entities (NCEs): Discovery and patenting of novel NK1 receptor antagonists with potentially improved efficacy, safety profiles, or different therapeutic applications.
- Combination Therapies: Patents covering the use of NK1 receptor antagonists in combination with other therapeutic agents to enhance treatment outcomes for various conditions.
- Advanced Delivery Systems: Similar to aprepitant, other NK1 antagonists may also face solubility challenges, leading to patenting of innovative formulations and delivery technologies.
Companies holding patents in this space aim to build a robust intellectual property portfolio that encompasses the molecule, its manufacturing, and its delivery. Patent 11,053,214 contributes to this landscape by addressing the specific formulation challenges of aprepitant, potentially creating a protected market for its amorphous dispersion technology. Analysis of patent expiration dates and potential for litigation is critical for competitive strategy in this segment.
What are the potential challenges or limitations of the technology claimed in Patent 11,053,214?
While the technology offers significant advantages, several potential challenges and limitations warrant consideration:
- Stability of Amorphous Form: Amorphous forms are thermodynamically less stable than crystalline forms and are prone to recrystallization over time, particularly under conditions of high humidity or temperature. The "stabilized" aspect of the claims suggests efforts to mitigate this, but long-term stability data and the specific stabilizing mechanisms will be critical. Factors like the choice of polymer, its molecular weight, and the ratio of drug to polymer influence this stability.
- Manufacturing Scalability and Cost: Processes like spray drying or hot melt extrusion, while effective for creating amorphous dispersions, can be complex and expensive to scale up. Ensuring reproducible particle properties and drug loading at commercial scale is a significant manufacturing challenge. The cost of specialized excipients can also impact the overall cost of goods.
- Excipient Compatibility: The interaction between aprepitant and the polymeric excipient is crucial. Incompatibility can lead to drug degradation, phase separation, or loss of amorphous character. Thorough compatibility studies are required.
- Regulatory Hurdles: Demonstrating the safety and efficacy of a new amorphous formulation, especially one intended to improve bioavailability, requires extensive preclinical and clinical testing. Regulatory agencies will scrutinize the manufacturing process, stability data, and pharmacokinetic profiles to ensure equivalence or superiority to existing crystalline formulations.
- Intellectual Property Landscape: While this patent provides protection, the broader patent landscape for aprepitant formulation technologies is crowded. Competitors may have existing patents on similar amorphous dispersion techniques or alternative solubility enhancement strategies that could pose infringement risks or require licensing agreements.
- Dosage Form Limitations: The physical properties of amorphous dispersions, such as hygroscopicity or flowability, can sometimes limit the types of dosage forms that can be manufactured (e.g., direct compression tablets might be challenging).
These factors necessitate a comprehensive evaluation of the technological feasibility, economic viability, and regulatory pathway for any product developed based on the claims of Patent 11,053,214.
What are the potential infringement risks for generic manufacturers?
Generic manufacturers seeking to market aprepitant products face potential infringement risks related to Patent 11,053,214, particularly if their product utilizes a stabilized amorphous dispersion of aprepitant.
- Direct Infringement: If a generic product is formulated as a stabilized amorphous dispersion of aprepitant with at least one polymeric excipient, as broadly defined in Claim 1, it would directly infringe upon this patent, assuming the crystalline content is less than 5% by weight.
- Method of Preparation Infringement: If a generic manufacturer employs a method for preparing an amorphous dispersion of aprepitant that falls within the scope of Claim 11, even if the final product composition differs slightly, they could be liable for infringement. This includes methods involving dissolving aprepitant and a polymer in a solvent and then removing the solvent.
- Indirect Infringement: Generic manufacturers could also face induced or contributory infringement if they knowingly sell components or provide instructions that facilitate the infringing use of their product by others, particularly if the product is specifically designed for an infringing application.
To mitigate these risks, generic manufacturers must conduct thorough freedom-to-operate (FTO) analyses. This involves:
- Claim Construction: Precisely interpreting the scope and limitations of the patent's claims.
- Product Analysis: Comparing their proposed product's composition, manufacturing process, and physical characteristics against each element of the patent's claims.
- Invalidity Challenges: Investigating grounds for challenging the validity of Patent 11,053,214, such as prior art that predates the patent's filing date or arguments regarding obviousness or lack of enablement.
- Alternative Formulations: Developing alternative formulations that do not fall within the scope of the patent, such as different salt forms, crystalline polymorphs with improved properties, or entirely different solubility enhancement techniques that are not covered by the claims.
The expiration date of Patent 11,053,214 is a critical factor. However, the patent term can be extended under certain circumstances, such as patent term adjustment (PTA) and patent term extension (PTE). A thorough understanding of these extensions is necessary for accurate risk assessment.
Key Takeaways
- United States Patent 11,053,214 protects stabilized amorphous dispersions of aprepitant and methods of preparation, aiming to improve solubility and bioavailability.
- Core claims define the amorphous composition, pharmaceutical compositions containing it, and specific preparation methods involving solvent removal.
- The patent specifies a range of polymeric excipients and solvent systems suitable for creating these amorphous dispersions.
- The technology enables enhanced therapeutic efficacy and potentially extends market exclusivity for improved aprepitant formulations.
- The patent landscape for aprepitant is competitive, with patents covering composition, process, polymorphs, and formulations.
- Potential challenges include stability of the amorphous form, manufacturing scalability, regulatory hurdles, and intellectual property complexities.
- Generic manufacturers face infringement risks if their products utilize stabilized amorphous dispersions or covered preparation methods, necessitating thorough FTO analyses.
Frequently Asked Questions
-
What is the primary technical innovation protected by U.S. Patent 11,053,214?
The primary innovation is the creation and stabilization of amorphous dispersions of aprepitant, overcoming its inherent poor aqueous solubility and enhancing its bioavailability through specific polymeric excipient combinations and manufacturing processes.
-
Can aprepitant be formulated into a generic drug without infringing Patent 11,053,214?
Yes, generic manufacturers can potentially develop aprepitant drugs that do not infringe, provided their formulations do not utilize the stabilized amorphous dispersion technology as claimed or the specific preparation methods described. This may involve using crystalline forms, different excipients, or alternative solubility enhancement strategies.
-
What is the expiration date of United States Patent 11,053,214?
United States Patent 11,053,214 was granted on July 20, 2021. Its standard expiration date is typically 20 years from the filing date, which for this patent was January 24, 2020. However, patent term adjustments and extensions could alter the actual expiration date.
-
What are the therapeutic indications for aprepitant that this patent aims to improve?
The patent's focus on improving aprepitant's solubility and bioavailability is primarily aimed at enhancing its efficacy for conditions like chemotherapy-induced nausea and vomiting (CINV), a primary indication for aprepitant.
-
How does an amorphous dispersion differ from a crystalline form of aprepitant?
In an amorphous dispersion, aprepitant exists in a disordered, non-crystalline solid state, typically dispersed within a polymer matrix. This contrasts with a crystalline form, where aprepitant molecules are arranged in a highly ordered, repeating three-dimensional lattice structure. Amorphous forms generally exhibit higher solubility and faster dissolution rates compared to their crystalline counterparts.
Citations
[1] Kim, B. J., Kim, M. H., Lee, J. H., Kim, Y. I., & Kim, H. K. (2021). Stabilized amorphous dispersions of aprepitant and methods of preparation thereof (U.S. Patent No. 11,053,214). United States Patent Office.
More… ↓
⤷ Start Trial
|
